CoChat

Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan

Open access

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Abstract

Background: As human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare chronic neurological disease, large scale studies to collect continuous clinical data have been difficult to conduct. Therefore, the incidence of comorbidities and drug utilization data remain unknown. When conducting trials to develop new drugs in rare disease such as HAM/TSP, historical control data obtained from registry studies would be useful, as cohorts in rare disease tend to be small. Long-term follow-up of patients with a chronic disease can also be challenging. In this study, we addressed the following two goals using registry data on patients (n = 486) enrolled in the Japanese HAM/TSP patient registry “HAM-net” from 2012 to 2016: 1) to clarify the epidemiological information of HAM/TSP such as the incidence of comorbidities and drug utilization and 2) to provide the real-world data on changes in lower limb motor dysfunction. Results: In HAM-net-registered patients, common comorbidities were fractures, herpes zoster, and uveitis, with incidences of 55.5, 10.4, and 6.5, respectively, per 1000 person-years. Every year, oral steroid treatment was administered in 48.2–50.7% of the HAM-net-registered patients and interferon-α treatment was used in 2.6–3.5% of patients. The median dose of oral prednisolone was low at 5.0 mg/day. The incidence of fractures and herpes zoster tended to be higher in the steroid-treated group than in the untreated group (fractures: 61.0 vs. 48.3, herpes zoster: 12.7 vs. 8.8, per 1000 person-years). The analysis of chronological change in Osame motor disability score (OMDS) indicated that the mean change in OMDS was + 0.20 [95% confidence intervals (CI): 0.14–0.25] per year in the one-year observation group (n = 346) and + 0.57 (95% CI: 0.42–0.73) over four years in the four-year observation group (n = 148). Significant deterioration of OMDS was noted in all subgroups with varying steroid use status. Conclusions: This study revealed the incidence of comorbidities and drug utilization data in patients with HAM/TSP using registry data. Furthermore, this study provided real-world data on chronological changes in lower limb motor dysfunction in patients with HAM/TSP, indicating the utility of these data as historical controls.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13023-019-1212-4

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart showing analysis sets to conduct a fact-finding survey for HAM/TSP. The entire analysis set in this study consisted of 486 patients enrolled sequentially in the HAM/TSP patient registry “HAM-net” from March 2012 to December 2016. All 486 patients received an initial telephone interview just after registration (a). Information obtained from this interview was considered as baseline. Subsequently, we conducted annual interviews. We regarded the 434 patients who received an annual interview for two consecutive years as a one-year observation group (b). Likewise, we considered the 370 patients interviewed annually for three consecutive years as a two-year observation group (c). The three-year observation and the four-year observation groups consisted of 304 (d) and 257 patients (e), respectively. See Methods for details
Fig. 1 Flowchart showing analysis sets to conduct a fact-finding survey for HAM/TSP. The entire analysis set in this study consisted of 486 patients enrolled sequentially in the HAM/TSP patient registry “HAM-net” from March 2012 to December 2016. All 486 patients received an initial telephone interview just after registration (a). Information obtained from this interview was considered as baseline. Subsequently, we conducted annual interviews. We regarded the 434 patients who received an annual interview for two consecutive years as a one-year observation group (b). Likewise, we considered the 370 patients interviewed annually for three consecutive years as a two-year observation group (c). The three-year observation and the four-year observation groups consisted of 304 (d) and 257 patients (e), respectively. See Methods for detailsCC BY · PubMed Central
Fig. 2 Flowchart for showing analysis sets to assess motor function in HAM/TSP (analysis set 2). To examine the chronological change of OMDS in patients with HAM/TSP, we excluded those who had factors that could affect the evaluation of lower limb motor function from 486 patients using specific exclusion/dropout criteria (see Methods for details). This cohort is referred to as “analysis set 2” in this paper. Furthermore, to accurately evaluate yearly changes in OMDS, we limited “analysis set 2” to patients whose interval between each survey date fell within 275–455 days (365 ± 90 days). The right half of this chart shows the number of patients who were excluded at each step and the reasons why. After being excluded by the criteria, there were 457 patients at the time of the initial interview (a). We used both the one-year observation group (n = 346, b) andthe four-year observation group (n = 148, e) for analysis. The two-year observation and the three-year observation groups consisted of 251 (c) and 175 patients (d), respectively
Fig. 2 Flowchart for showing analysis sets to assess motor function in HAM/TSP (analysis set 2). To examine the chronological change of OMDS in patients with HAM/TSP, we excluded those who had factors that could affect the evaluation of lower limb motor function from 486 patients using specific exclusion/dropout criteria (see Methods for details). This cohort is referred to as “analysis set 2” in this paper. Furthermore, to accurately evaluate yearly changes in OMDS, we limited “analysis set 2” to patients whose interval between each survey date fell within 275–455 days (365 ± 90 days). The right half of this chart shows the number of patients who were excluded at each step and the reasons why. After being excluded by the criteria, there were 457 patients at the time of the initial interview (a). We used both the one-year observation group (n = 346, b) andthe four-year observation group (n = 148, e) for analysis. The two-year observation and the three-year observation groups consisted of 251 (c) and 175 patients (d), respectivelyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Toyama N, Shiraki K. Epidemiological studies on varicella zoster in Miyazaki Prefecture. Infectious Agents Surveillance Report (IASR). 2013;34:298–300.

Cited by

See all 33

Metadata

Authors
Tsutsumi, S., Sato, T., Yagishita, N., Yamauchi, J., Araya, N., Hasegawa, D., Nagasaka, M., Coler-Reilly, A. L. G., Inoue, E., Takata, A., & Yamano, Y.
Affiliations
St. Marianna University School of Medicine (JP)
Corresponding author
Yamano, Yoshihisa
Venue
Orphanet Journal of Rare Diseases
Published
2019-10-21
Volume
14
Issue
1
Pages
227-227
ISSN
1750-1172 (ISSN-L)
OpenAlex
W2980605760
Cited by
33
References
24
Citations by year
2026: 6 · 2025: 2 · 2024: 7 · 2023: 5 · 2022: 5 · 2021: 2 · 2020: 6
FWCI
1.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Japan Agency for Medical Research and Development (JP19ek0109346, JP19ek0109356, JP19ek0109394)
  • Ministry of Health, Labour and Welfare (19FC1007)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
  • Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords
HAM/TSP, tropical spastic paraparesis, comorbidities, medication use, oral corticosteroids, prednisolone, interferon-alpha, fracture, herpes zoster, uveitis, disease progression, rare disease registry, Japan
MeSH terms
Aged, Cross-Sectional Studies, Female, Humans, Japan, Male, Middle Aged, Retrospective Studies, Steroids, Human T-lymphotropic virus 1, Paraparesis, Tropical Spastic, Incidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. https://app.cochat.ai/papers/10.1186/s13023-019-1212-4
The paper
Tsutsumi, S., Sato, T., Yagishita, N., Yamauchi, J., Araya, N., Hasegawa, D., Nagasaka, M., Coler-Reilly, A. L. G., Inoue, E., Takata, A., & Yamano, Y. (2019). Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-019-1212-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.